1 / 65

HYPERTENSION and the use of ANTI-HYPERTENSIVES Joshua M.Crasner, DO,FACC,FACOI

HYPERTENSION and the use of ANTI-HYPERTENSIVES Joshua M.Crasner, DO,FACC,FACOI. JNC-6 (old criteria). JNC-7 Definition of HTN. JAMA 289; 2560-72: 2003. TYPES OF HYPERTENSION SYSTOLIC AND DIASTOLIC. Primary(Essential, Idiopathic) Secondary Renal: Acute GN, Diabetic Nephropathy

maeko
Télécharger la présentation

HYPERTENSION and the use of ANTI-HYPERTENSIVES Joshua M.Crasner, DO,FACC,FACOI

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. HYPERTENSION and the use of ANTI-HYPERTENSIVESJoshua M.Crasner, DO,FACC,FACOI hypertension

  2. JNC-6 (old criteria) hypertension

  3. JNC-7 Definition of HTN JAMA 289; 2560-72: 2003 hypertension

  4. hypertension

  5. TYPES OF HYPERTENSIONSYSTOLIC AND DIASTOLIC • Primary(Essential, Idiopathic) • Secondary • Renal: Acute GN, Diabetic Nephropathy • Endocrine: TSH, cortisol, calcium • aortic coarctation • pregnancy-induced • neurologic: tumor, sleep apnea • stress: surgery, burns, EtOH withdrawal,S.cell • Drugs: decongestants, antidepressants, OCP hypertension

  6. RED FLAGS FOR SECONDARYHYPERTENSION • Abdominal bruit: renal artery stenosis • Palps,HA,pallor,perspiration: pheochromocytoma • Obesity,moon face,purple striae: Cushing’s • Abd mass: polycystic kidney,hydroneph • Obesity,hypersomnolence: OSAS • Agitation, sweating: cocaine, ethanol • Hypokalemia: hyperaldosteronism • Hypercalcemia: hyperparathyroidism hypertension

  7. hypertension

  8. TYPES OF HYPERTENSIONSYSTOLIC • Increased Cardiac Output: • aortic regurgitation, PDA/AVF, thyrotoxicosis, Paget’s disease • Aortic rigidity hypertension

  9. HYPERTENSION WITH AGE • Systolic BP rises continuously with age • Diastolic rises up to age 50, then falls • Pulse pressure then widens with age Vasan, et al.JAMA, 2002; 287(8):1003-10 hypertension

  10. hypertension

  11. hypertension

  12. ETIOLOGY HTN • “essential” > 90 % • Genetics, environment • African descent and elderly have low renin; more sensitive to salt and volume • non-African/young pts. have high renin hypertension

  13. ESSENTIAL HYPERTENSION • Most common HBP( > 90 %)--multifactorial • increased peripheral resistance perpetuates the process of high blood pressure and all of its secondary effects • structural hypertrophy giving rise to smooth muscle hypercontractility • pressure varies throughout the day • major risk factor for coronary, renal, and cerebrovascular disease (50% of all USA deaths) • leading cause of doctor’s visit • carries prognostic value: 16X increased risk 40 y.o. smokes hypertension

  14. TARGET ORGAN DAMAGELeft Ventricular Hypertrophy • End result of hypertensive heart disease • structural adaptation to pressure overload • initially adaptive and later pathologic • mass >100-130 g/m2 hypertension

  15. TARGET ORGAN DAMAGELEFT VENTRICULAR HYPERTROPHY • Eccentric: isotonic exercise, increased volume load mass/volume ratio low • Concentric: isometric exercise, increased pressure load mass/volume ratio high • degree does not correlate with blood pressure • Prognostic value: • sudden cardiac death, ischemia/decreased coronary flow, CHF, • increased vascular tone • Who? • Increases with age • 2-3 more times likely in obese • athletes • African descent higher LV mass response hypertension

  16. TARGET ORGAN DAMAGELEFT VENTRICULAR DYSFUNCTION • Diastolic dysfunction • reduced rate rapid early filling/incr.atrial portion • correlates with degree of LVH • CHF • Systolic dysfunction • less common as BP tighter controlled • myofibril degeneration/lysis • occurs late • CHF: will predispose to other causes(CAD, valve) hypertension

  17. TARGET ORGAN DAMAGECORONARY ARTERY DISEASE • HTN accelerates progression of CAD • increased oxygen demand • increased silent MI/sudden cardiac death/infarct size(33%) • ischemia caused by diastolic dysfunction • oxygen demand is different than for epicardial occlusion hypertension

  18. hypertension

  19. TARGET ORGAN DAMAGERENAL DISEASE • Increased intraglomerular hypertension • loss of concentrating ability • nocturia • reduced creatinine clearance • albuminuria • salt and water retention • HTN is the leading cause of ESRD • nephrosclerosis hypertension

  20. hypertension

  21. TARGET ORGAN DAMAGECEREBRO/PERIPHERAL VASCULARDISEASE • major risk factor for CVA/TIA • similar physiology hypertension

  22. hypertension

  23. hypertension

  24. DETECTION OF HYPERTENSIVE HEART DISEASE • PHYSICAL EXAM • ELECTROCARDIOGRAM • 2-D ECHOCARDIOGRAM • STRESS TESTING • LAB TESTING hypertension

  25. PHYSICAL EXAM • Forceful sustained apical impulse early • S4 gallop early • S3 gallop later • LV dilation: laterally displaced apical impulse hypertension

  26. BP MEASUREMENT • Patient seated/back supported/feet on floor • Should rest 5 minutes prior • Arm at heart level • No recent caffeine, tobacco, cocaine • Take medications as directed • Cuff size important • orthostatics hypertension

  27. hypertension

  28. ELECTROCARDIOGRAM • All patients should have as baseline • no LVH on ECG does not mean no LVH in vivo • the presence of LVH suggests target end organ damage…….poorer prognosis • Left atrial enlargement? • Conduction abnormalities hypertension

  29. 2D ECHOCARDIOGRAM • Wall thickness • chamber size • systolic and diastolic function • valve pathology hypertension

  30. 2-D Echo (Parasternal Long Axis) • The parasternal long axis view is obtained from the left sternal border. • Displayed in this view: • RV • IVS • LV • Aortic Valve (AV) • Mitral Valve (MV) • Left Atrium (LA) RV LV Apex IVS LV Aortic Valve Mitral Valve Left Atrium hypertension

  31. Motion Mode (M-Mode) • In M-Mode, the motion of all cardiac structures along the sample line is displayed over time (left to right) • Systole and Diastole are evident by the decrease in LV cavity size. • The motion of the IVS and LV Posterior wall are synchronous in contraction. hypertension

  32. DIASTOLIC DYSFUNCTION hypertension

  33. hypertension

  34. hypertension

  35. hypertension

  36. hypertension

  37. DIASTOLIC DYSFUNCTION hypertension

  38. DIASTOLIC DYSFUNCTION hypertension

  39. DIASTOLIC DYSFUNCTION hypertension

  40. STRESS TESTING • Detects patients at increased risk • silent ischemia/subclinical CAD • hypertensive response portends poor prognosis hypertension

  41. LAB TESTING • Urine analysis • Chemistry panel • Cholesterol • CBC • Endocrine • Drug screen? hypertension

  42. GOALS AT FIRST EVAL. • Diagnose secondary or remediable causes • Uncover target organ damage • Identify coexisting risk factors that could affect treatment plans hypertension

  43. hypertension

  44. TREATMENT OF HYPERTENSION • Prevent development/progression of LVH • JNC-7: 120/80 optimal • reduction of target organ damage: brain, heart, kidney, eyes • pharmacologic • Lifestyle modifications hypertension

  45. hypertension

  46. LIFESTYLE MODIFICATION hypertension

  47. hypertension

  48. hypertension

  49. hypertension

  50. PHARMACOLOGIC TREATMENT OF HYPERTENSION • inhibitors of the renin-angiotensin system a must in diabetic, renal, or CAD patients • identify co-morbidities (slide 19) • ACE inhibitors/A-II blockers • Calcium channel blockers • Beta blockers • diuretics • alpha blockers • central agents • vasodilators hypertension

More Related